Could this pill beat long COVID fatigue?

NCT ID NCT07298005

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether the drug sonlicromanol can reduce fatigue in 80 people with long COVID who experience post-exertional malaise (worsening symptoms after activity). Participants take the drug or a placebo twice daily for 13 weeks, and researchers measure changes in fatigue, muscle strength, and thinking ability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sonlicromanol

What this could lead to

If it works, this could point toward a treatment for severe fatigue in people with long COVID.

What could go wrong

This is a small, early-phase trial with only 80 participants. The drug may not reduce fatigue better than a placebo, and it is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-COVID CONDITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam University Medical Center, Location Academic Medical Center (AMC)

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••